Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Targeting CAR-NK Cells in Recurrent or Refractory Ovarian Cancer
NCT07480954Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DT-CAR-NK in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC), fallopian tube carcinoma (PFTC), sponsored by Biotech Pharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
EB-DT-CAR-NK
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT07480954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480954.